Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Net Income towards Common Stockholders: 2019-2023

Historic Net Income towards Common Stockholders for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to -$45.3 million.

  • ADC Therapeutics' Net Income towards Common Stockholders fell 189.52% to -$45.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$153.5 million, marking a year-over-year decrease of 216.62%. This contributed to the annual value of -$155,800 for FY2022, which is 32.27% up from last year.
  • Latest data reveals that ADC Therapeutics reported Net Income towards Common Stockholders of -$45.3 million as of Q3 2023, which was up 6.01% from -$48.2 million recorded in Q2 2023.
  • ADC Therapeutics' 5-year Net Income towards Common Stockholders high stood at $126.6 million for Q2 2020, and its period low was -$60.0 million during Q1 2023.
  • Its 3-year average for Net Income towards Common Stockholders is $15.8 million, with a median of $16.7 million in 2022.
  • Per our database at Business Quant, ADC Therapeutics' Net Income towards Common Stockholders soared by 477,493.44% in 2020 and then crashed by 459.82% in 2023.
  • Over the past 5 years, ADC Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$35,285 in 2019, then soared by 64,960.73% to $20.3 million in 2020, then spiked by 251.97% to -$34,381 in 2021, then climbed by 29.74% to -$24,157 in 2022, then crashed by 189.52% to -$45.3 million in 2023.
  • Its last three reported values are -$45.3 million in Q3 2023, -$48.2 million for Q2 2023, and -$60.0 million during Q1 2023.